Company search

  1. Home
  2. Company search

Company search

KOBE Life Science Cluster Company List

Business Expansion
on Kobe's Port Island

349

companies

as of March 31, 2025

Companies are divided into categories by their major business field on Kobe Port Island. In the case they have other business fields, it is shown in the minor field.» List of KBIC companies(PDF)

≫ StartupsStartups Company List

Search by Company name or Keyword

Entities are classified mainly by their business activities in the South area of KOBE Port Island.

Location search results Translational Research Informatics Center(TRI)

1～ 4of Results 4

Re-search in Location

Bacchus Bio innovation Co., Ltd.

Major field： Material and Chemical Products

Miner field： Contract Research

Miner field： Production of Drugs and Quasi Drugs

Integrated biofoundry

Overview

Utilizing biotechnology (genome editing technology, DNA synthesis technology, etc.) and digital technology (IT and AI), we can design microorganisms to produce new substances (Design), create the designed microorganisms (Build), select excellent microorganisms from among the created microorganisms (Test), and analyze the measured data from the constructed microorganisms (Learn). The DBTL flow is rotated at a high speed to enhance functions and add new functions to microorganisms, including the integrated analysis of measured data (Learn). We can efficiently produce various substances such as pharmaceutical raw materials, fuels, plastics, food additives, and cosmetic raw materials.

Product / Service / PR

    In health and medical industry, even if a drug candidate with excellent efficacy and effectiveness is discovered, product development is often suspended because it cannot be mass-produced or commercialized using conventional chemical synthesis and cultivation methods. Our technology enables the efficient production of pharmaceutical raw materials or intermediates of microbial origin, and contributes to the reduction of drug prices of existing products.
Address： Head office location
1-1 Rokkodai-cho, Nada-ku, Kobe, Hyogo 657-0013, Japan　
Bio-Foundry
6-3-7 Minatojima Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan Creative Lab Kobe 505　
（Contact Person　 Shogo Harumoto）
TEL： +81-78-599-5717 FAX： +81-78-599-5718
Web site： https://www.b2i.co.jp/ E-mail： info@b2i.co.jp

CynosBio, Inc.

Major field： Regenerative Medicine

Miner field： Drug Discovery

Development, manufacturing, and marketing of regenerative medicine products

Overview

Development, manufacturing and supply of regenerative and other medical products

Product / Service / PR

    CynosBio, Inc. is the first unlisted domestic company to commercialize regenerative medicine products.
    Under the bridging research led by the Foundation for Biomedical Research and Innovation at Kobe (FBRI), the company is engaged in the development, manufacturing, and sales of regenerative medicine products introduced from academia (such as university hospitals).
    In 2022, the company achieved the approval and insurance listing of the oral mucosa-derived epithelial cell sheet "TR-9 (Sakuracy®)" using amniotic membrane matrix, a product researched at Kyoto Prefectural University of Medicine. This achievement has provided a new treatment for diseases that were previously difficult to treat.
    Currently, the company is focused on the development of a treatment for osteoarthritis of the knee using the autologous cartilage cell processing product "IK-01." The disease, which is said to affect approximately 25 million people, including potential patients in Japan, is the target of corporate clinical trials.
    The company will continue to focus on technological innovation in regenerative medicine and research in cell culture technologies, striving to offer innovative treatments utilizing the power of regenerative medicine for diseases that are difficult to treat.
Address： 1-3-15 Nihonbashi Horidome-cho, Chuo-ku, TOKYO, JAPAN.　 （Contact Person　 Kousuke Oota）
TEL： +81-36-457-9861 FAX： +81-36-261-4445
Web site： https://cynosbio.com/about/ E-mail： info.tokyo@cynosbio.com

Cyto-Facto Inc.

Major field： Regenerative Medicine

Miner field： Contract Research

Miner field： Production of Drugs and Quasi Drugs

Specialized in manufacturing cell and gene products as CDMO

Overview

Services we provide in the field of cell & gene therapy
1. Contracted manufacturing of commercial products (CMO)
2. Process development and manufacturing of clinical products (CDMO)
3. Quality control testing of CGT products for commercial, clinical and research use
4. Development, sales, and service business of manufacturing management systems
5. Consultation for regulatory issues

Product / Service / PR

    Cyto-Facto (its predecessor, the RDC of the FBRI) is the first Asian company to manufacture commercial CAR-T products in compliance with PIC/S GMP. Cyto-Facto has accumulated experience in manufacturing technology know-how and has launched several cell & gene manufacturing pipelines, including CAR-T, iPSC-based cells and mesenchymal stem cells (MSCs) of various developmental stages.
Address： Shimin Byoin Mae Bldg. 3F, 2-1-11 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047 Japan　 （Contact Person　 General Affairs and Human Resources）
TEL： +81-78-306-0681
Web site： https://www.cytofacto.com/eng/ E-mail： info@cytofacto.com

HEALIOS K.K.

Major field： Regenerative Medicine

Research, development, manufacture of cell therapy products and regenerative medicine products

Overview

Raising our mission, “To be the change in an ever evolving world through enrichment of living”, HEALIOS was established in 2011 via Riken Venture system.
We are dedicated to develop promising medicines to heal and bring hope to those worldwide who are suffering from incurable diseases by making use of the regenerative power.

Product / Service / PR

    [Somatic stem cell regenerative medicine]
    Development of regenerative medicine for ischemic stroke and Acute Respiratory Distress Sydrome (ARDS) in Japan using MultiStem®, products developed by Athersys, Inc.
    [iPSC regenerative medicine]
    Development of Treatments for Age-Related Macular Degeneration (AMD) involving transplantation of iPS cell-derived retinal pigment epithelial (RPE) cells.
    Development of Organ Bud Transplantation Therapy involving a technology to create functional human organs using iPS cells.
Address： Kobe KIMEC Center Building 3F, 1-5-2 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan　
Web site： https://www.healios.co.jp/en/ E-mail： info@healios.jp